You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
申聯生物(688098.SH)2019年度淨利降10.99%至7795.72萬元 擬10派0.8元
格隆匯 04-23 21:24

格隆匯4月23日丨申聯生物(688098.SH)發佈2019年年度報告,實現營業收入2.538億元,同比減少7.75%,其中獸用生物製品營業收入為2.537億元;歸屬於上市公司股東的淨利潤7795.72萬元,同比減少10.99%;歸屬於上市公司股東的扣除非經常性損益的淨利潤6792.61萬元,同比減少17.36%;基本每股收益0.21元;擬每10股派送現金紅利0.8元(含税)。

公司新產品豬口蹄疫O型、A型二價合成肽疫苗(多肽2700+2800+MM13)於2018年12月底取得產品批准文號,公司迅速組織生產準備,以最快的速度將產品投放市場,並積極開展新產品推廣工作,加大客户培訓力度,新產品銷售額快速增長,部分對衝了非洲豬瘟疫情對公司產品銷售的負面影響。

2019年2月,蘭州分公司新建“懸浮培養口蹄疫滅活疫苗”項目第一條生產線通過GMP靜態驗收,之後進入試生產階段,2019年底完成工藝定型。公司新建動物房按照生物安全三級防護標準要求設計和建設,並已完成第三方檢測。上海總公司診斷試劑車間免疫學A類生產線已通過GMP動態驗收。未來這些新產品線的投產,將為公司產品升級和多元化奠定堅實基礎。

報告期公司研發費用為2656萬元,同比增加24.79%,佔營業收入的比例為10.47%,從而保證公司研發項目有序推進。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account